Navigation Links
TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
Date:10/20/2008

LA JOLLA, Calif., Oct. 20 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced it initiated dosing of the first cohort of subjects in a Phase I multiple dose clinical trial of NGX426, the oral prodrug of its most advanced product candidate, tezampanel. The trial is designed to evaluate the safety, tolerability and pharmacokinetics of NGX426 when given once daily for five consecutive days. NGX426 has been safely administered to more than 150 healthy adults in single doses from 10 to 210 mg. Data from the multiple dose trial will support the development of NGX426 in chronic pain indications such as neuropathic pain.

The double-blind, placebo-controlled, Phase I multiple dose trial is being conducted at a single center in the United States. A total of 20 healthy male and female adult volunteers will be enrolled in two sequential dose-escalating cohorts and will receive once daily oral doses of placebo, 90 mg or 150 mg of NGX426 for five consecutive days. These same dose strengths of NGX426 are currently being evaluated by TorreyPines in a Phase I single dose capsaicin induced hyperalgesia trial to evaluate the analgesic effect of NGX426. Results from this single dose trial are expected to be announced in December 2008.

"We are pleased with our development progress for NGX426. This novel, oral, non-opioid product candidate could potentially address significant unmet needs in treating migraine and other forms of chronic pain such as neuropathic pain," said Ev Graham, acting chief executive officer of TorreyPines Therapeutics. "The multiple dose trial, as well as the ongoing Phase I capsaicin trial evaluating the analgesic effect of NGX426, will guide us in planning our Phase II program."

Tezampanel
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
2. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
3. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
4. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
5. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
6. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
7. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
8. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
9. TorreyPines Therapeutics Reports Third Quarter 2007 Results
10. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
11. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Research ( http://www.bccresearch.com ) reveals in its new report, ... MARKETS , the global market for digital polymerase chain ... This is estimated to grow to $490 billion in ... of 28.6%. , New digital PCR technology has created ... broader PCR field. The opportunities presented by this technology ...
(Date:7/11/2014)... - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today announced that ... use as a once-daily adjunctive therapy for the treatment ... not satisfactorily controlled with conventional therapy.  APTIOM TM ... years of age. Epilepsy is one ... Epilepsy Canada, it affects 0.6% of the population and ...
(Date:7/11/2014)... 2014 Cayenne Medical, Inc., a ... the soft tissue reconstruction segment, announced the worldwide ... surgeries involving the shoulder and extremities. The SureLock ... inserter-controlled deployment method. The unique delivery eliminates manual ... pull-out, or anchor displacement (also commonly know as ...
(Date:7/10/2014)... Product and process impurities in biopharmaceuticals ... are often “lost in the noise,” making their ... Dr. Rowel Tobias, Senior Scientist, Protein Chemistry at ... Quality at Nanotherapeutics, Inc., to lear about a ... and quantitation while achieving the required specificity and ...
Breaking Biology Technology:Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2
... to use anti-theft software Rockwell signs agreement ... for data imaging Wisconsin bankers ... of Wisconsin will be the first state banking association ... announced on Wednesday at BAI's Retail Delivery Conference and Expo ...
... place inside the Monona Terrace. (Jason Stitt/WTN) Angel ... of Wisconsins continually evolving technology culture at the ... and Wednesday at the Monona Terrace. , ,Biotech companies ... panels studied the future of the states industry. , ...
... Wisconsin Institute for Discovery It was inevitable that ... interdisciplinary research center on the UW-Madison campus would be ... a $3 billion, 10-year initiative to fund human embryonic ... research is a sizable part of what will happen ...
Cached Biology Technology:Life-sciences conference showcases capital ideas of Wisconsin 2Life-sciences conference showcases capital ideas of Wisconsin 3Doyles proposal is about more than keeping pace with California 2Doyles proposal is about more than keeping pace with California 3
(Date:7/11/2014)... Social animals often develop relationships with other group members ... In wild chacma baboons the strategy for grooming activities ... are just published in the scientific journal Biology ... of baboons is not practiced without ulterior motives. To ... for the individual, while grooming another individual can provide ...
(Date:7/11/2014)... July 11, 2014 Researchers have pioneered a ... The new technology, called Virtual Finger, allows scientists ... like neurons and synapses using the flat surface ... makes 3D imaging studies orders of magnitude more ... unprecedented level across many areas of experimental biology. ...
(Date:7/11/2014)... marginal division of the striatum is also involved ... degree of substance P in the striatal marginal ... and his team, College of Biophotonics, South China ... substance P receptor, neurokinin 1 was highly expressed ... normal rats. Unilateral or bilateral injection of an ...
Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... - an antibacterial chemical found in toothpaste and other ... allergy development in children. This comes from the Norwegian ... Institute of Public Health is involved. Similar results are ... in use for decades, but was recently associated with ...
... is when a horse shakes or jerks its head ... similarities between facial pain syndromes in people, most notably ... has been made towards both diagnosing and treating the ... unknown and further research is needed. ...
... in combination with other measures, could significantly improve numbers ... a fish modelling study has found., Scientists working at ... Secretariat of the Pacific Community (SPC, Noumea, New Caledonia) ... that a network of marine zones in the Pacific ...
Cached Biology News:Triclosan in cosmetics and personal care products can increase allergy risk 2Study investigates headshaking in horses 2Pacific fishing zones -- lifeline for overfished tuna? 2
... Chicken polyclonal to Opsin 1 ( Abpromise ... Antigen: Synthetic peptide: YEDSTHASIFTYT, corresponding to amino ... and synthetic peptide corresponding to amino acids 18/30 ... and used as immunogen. Entrez ...
Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
Request Info...
Myt 1 (N-17)...
Biology Products: